Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.

ABSTRACT: The pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations. Our population analysis aims to establish percentile curves for rilpivirine concentrations in people with HIV (PWH) followed-up in a routine clinical setting, while identifying patient-related factors that may influence rilpivirine exposure. A total of 238 PWH enrolled in our nationwide multicenter observational study contributed to 1038 concentrations (186 and 852 concentrations after oral and intramuscular injection, respectively). Rilpivirine pharmacokinetics were best described by a two-compartment model with an oral to intramuscular relative bioavailability factor. A simple zero-order absorption process was

SUBMITTER: Thoueille P 

PROVIDER: S-EPMC11605395 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature